- Samsung Biologics has completed the spin-off of Samsung Bioepis, establishing Samsung Epis Holdings to strengthen its focus as a pure-play CDMO.
- The company plans to expand production capacity to 1,324,000 litres by 2032 and broaden its portfolio to next-generation modalities, including ADCs and organoids.
Samsung Biologics has announced the completion of its spin-off of Samsung Bioepis, finalising the establishment of Samsung Epis Holdings as part of its strategy to operate as a pure-play Contract Development and Manufacturing Organization (CDMO).
The separation, approved by the company’s Board of Directors, was completed on 1 November following shareholder approval at the Extraordinary General Meeting held on 17 October. The spin-off received 99.9% shareholder support, reflecting strong confidence in the company’s strategic direction.
Samsung Biologics will continue trading following a temporary pause, with shares set to resume on 24 November, alongside the new listing of Samsung Epis Holdings.
With the restructuring complete, Samsung Biologics plans to accelerate its global growth through three strategic pillars: expanding manufacturing capacity, diversifying its service offerings, and strengthening its global footprint. The company aims to complete construction of its second Bio Campus by 2032, which will increase total production capacity to 1,324,000 litres, reinforcing its position as the world’s largest biomanufacturer.
Currently serving 17 of the world’s top 20 pharmaceutical companies, Samsung Biologics intends to extend its client base to the top 40 global biopharma firms, with additional expansion planned across Japan and the Asia-Pacific region.
“Through this spin-off, we have solidified our position as a pure-play CDMO and established a firm foundation for continued global growth. We remain committed to strengthening operational excellence and creating enduring value for our clients and the patients they serve.”
John Rim, President and CEO of Samsung Biologics
